The Trump administration’s push to bring US drug spending down is a powerful incentive for pharmaceutical companies to boost prices and reduce access elsewhere in the world, a study found.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
Trump’s Drug-Pricing Push to Cut Access Outside US, Study Finds
